About this episode
In our mini-series The Tox Talks we explore botulinum toxins: brands, the evolution of injecting technique and the subtle nuances of getting the best results.
In Chapter 13, Dr Jake Sloane and David Segal review the state of the toxin market and what more choice means for clinics. In Australia, injectors have quickly gone from three traditional options (Botox, Dysport and Xeomin) to seven, with the addition of Letybo, Nuceiva, Relfydess and Daxxify, creating new clinical and commercial complexity.
Patient demand, marketing pressure and questionable business choices have led some injectors to stock multiple brands, potentially at the expense of mastery, consistent results, patient satisfaction and profit. We outline the common issues when introducing a new toxin, and the business angles: inventory management, buying power, pricing and communicating change to patients.
What you'll learn
- How the neurotoxin market has evolved, and what seven brands means for clinics
- Whether brand differences really matter in practice
- Stocking one brand versus several
- Switching patients between toxins and preparing them for the change
- Dose, dilution and hyper-concentrated treatments
- Inventory, buying power, pricing and cashflow
Topics
- The Tox Talks
- Botulinum toxin
- Toxin brands
- Switching toxins
- Dosing
- Pricing
- Inventory management
- Cashflow
Full transcript
The full transcript for this episode is coming soon.